HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization

  • Authors:
    • Hanna Kim
    • Su-Nam Kim
    • Yeon-Suk Park
    • Nam Hyun Kim
    • Jeung Whan Han
    • Hoi Young Lee
    • Yong Kee Kim
  • View Affiliations

  • Published online on: December 17, 2010     https://doi.org/10.3892/ijo.2010.879
  • Pages: 807-812
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although histone deacetylase (HDAC) inhibitors are emerging as a promising class of cancer chemotherapeutic agents, their effects on multidrug resistance (MDR) are poorly understood. In this study, we investigated whether HDAC inhibitors overcome MDR phenotype. HDAC inhibitors suppress the growth of both MDR positive cancer cells KBV20C and its parental cells KB with similar potencies. In parallel, histone acetylation and p21WAF1 expression by the HDAC inhibitors were similarly increased in both cell types, indicating that these HDAC inhibitors are poor substrates of ABC drug transporters and effective in MDR cancer cells. In addition, multidrug resistance protein 2 (MRP2) expression is selectively attenuated by HDAC inhibitors, especially SAHA and TSA, in KBV20C cells, whereas MDR1 and BCRP expressions are not affected. This downregulation of MRP2 contributes to increase in paclitaxel-induced G2/M arrest and apoptosis, which might be due to intracellular accumulation of paclitaxel. Collectively, our data provide a molecular rationale for the application of HDAC inhibitors to overcome MDR in cancer cells.

Related Articles

Journal Cover

March 2011
Volume 38 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim H, Kim S, Park Y, Kim NH, Han JW, Lee HY and Kim YK: HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization. Int J Oncol 38: 807-812, 2011
APA
Kim, H., Kim, S., Park, Y., Kim, N.H., Han, J.W., Lee, H.Y., & Kim, Y.K. (2011). HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization. International Journal of Oncology, 38, 807-812. https://doi.org/10.3892/ijo.2010.879
MLA
Kim, H., Kim, S., Park, Y., Kim, N. H., Han, J. W., Lee, H. Y., Kim, Y. K."HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization". International Journal of Oncology 38.3 (2011): 807-812.
Chicago
Kim, H., Kim, S., Park, Y., Kim, N. H., Han, J. W., Lee, H. Y., Kim, Y. K."HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: Implication for chemosensitization". International Journal of Oncology 38, no. 3 (2011): 807-812. https://doi.org/10.3892/ijo.2010.879